Tuberculosis Associated with Infliximab, a Tumor Necrosis Factor α–Neutralizing AgentJoseph Keane, M. Miles Braun, Sharon K. Gershon et al.|New England Journal of Medicine|2001Cited by 3.7k
Tumor necrosis factor antagonist therapy and lymphoma development: Twenty‐six cases reported to the Food and Drug AdministrationS Brown, M. Miles Braun, Mark H. Greene et al.|Arthritis & Rheumatism|2002Cited by 661
Case Reports of Heart Failure after Therapy with a Tumor Necrosis Factor AntagonistHyon‐Jo Kwon, M. Miles Braun, Timothy R. Cot et al.|Annals of Internal Medicine|2003Cited by 459
Life‐threatening histoplasmosis complicating immunotherapy with tumor necrosis factor α antagonists infliximab and etanerceptJong‐Hoon Lee, M. Miles Braun, Nancy R. Slifman et al.|Arthritis & Rheumatism|2002Cited by 448
Surveillance for safety after immunization: Vaccine Adverse Event Reporting System (VAERS)--United States, 1991-2001.Weigong Zhou, Robert T. Chen, Vitali Pool et al.|PubMed|2003Cited by 397